BOSTON, May 10, 2023 (Newswire.com) - Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of off-the-record discussions and networking at its Spring MIT Longwood Healthcare Leaders Conference, co-hosted by Nobelist and Alnylam/Biogen Co-Founder Phillip Sharp, Ph.D., at The Koch Institute at MIT June 7-8, 2023.
The industry-leading conference focuses on a broad spectrum of topics affecting the biopharma ecosystem. BioPharma C-suite executives, heads of research and development, therapeutic area heads, leading academics, and life science investors will join discussions centering on ideas, strategies, and insights to help the industry translate groundbreaking discoveries into medicines to help patients.
Hosted by life science venture firm Longwood Fund, industry leaders will speak in fireside chats, roundtables, and discussion panels. Speakers include MIT Institute Professors Phil Sharp and Bob Langer, FDA Center for Biologics Evaluation and Research (CBER) Director Peter Marks, Takeda CEO Christophe Weber, Genentech CEO Alexander Hardy, Eisai CEO Ivan Cheung, Mass General Brigham President & CEO Anne Klibanski, Harvard Medical School Dean George Daley, Amgen head of R&D Dave Reese, Biogen CMO Maha Radhakrishnan, Ipsen CEO David Loew, Verve Therapeutics CEO Sek Kathiresan, former Alnylam CEO John Maraganore, BioNTech Chief Strategy Officer Ryan Richardson, Moderna CCO Arpa Garay, GlaxoSmithKline research head John Lepore, Astellas CMO Tadaaki Taniguchi, among others.
Topics include launching biotech companies, explosion of modalities, big biopharma R&D, data science enablement, accelerating drug development, optimizing translational research, the intersection of policy and science, drug pricing and reforms, and raising and managing capital, among others.
Drs. Phil Sharp and Bob Langer will share remarks at a cocktail reception for meeting participants at the close of the conference. To learn more, visit www.longwoodhealthcareleaders.com/spring2023.
Longwood Fund is a venture capital firm dedicated to creating and investing in novel healthcare companies that develop important treatments to help patients while generating significant value for investors. The Longwood team has a long history of successfully launching and building important life science companies while providing operational leadership and strategic guidance. Collectively, the Partners at Longwood Fund have co-founded 24 companies with over 20 launched or marketed drugs and therapies, as well as over two dozen clinical stage assets, all focused on helping patients in need. Companies founded by Longwood Fund, or its principals prior to the founding of the Firm, as lead investor and CEO/CBO include Acceleron, Momenta, Alnylam, Vertex, Sirtris, Vor, TScan, Pyxis Oncology, Immunitas, Be Biopharma, Tome Bio, Photys, Carbon Biosciences, and DEM BioPharma. For more information, visit www.longwoodfund.com.
Longwood Healthcare Leaders
As part of the Longwood Healthcare Leaders series, Longwood hosts semiannual industry conferences with thought leaders and decision makers in government, pharma, biotech, and academia for off-the-record forums at institutions including Harvard Medical School and MIT to discuss areas of collaboration and access to innovation in order to accelerate the translation of discoveries into medicines to help patients. For more information, visit www.longwoodhealthcareleaders.com.Contact Information:
Director, Investor Relations
Original Source: Longwood Healthcare Leaders to Convene Top Biotech and Pharmaceutical Leaders at MIT Koch Institute